MedTrace Logo

Tazemetostat Expanded Access Program for Adults With Solid Tumors

NCT03874455 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2024-03-22

No results posted yet for this study

Summary

Patients with a diagnosis listed under "conditions" below are eligible to be considered for the EAP. These conditions must be serious or life-threatening at the time of enrollment and appropriate, comparable, or satisfactory alternative treatments must have been tried without clinical success. Patients with conditions not listed under "conditions" below are not eligible for the tazemetostat EAP.

Conditions

  • Epithelioid Sarcoma (Ex-US Only)
  • Spindle Cell Sarcoma
  • Sinonasal Carcinoma
  • Small Cell Carcinoma of the Ovary Hypercalcemic Type
  • Thoracic Sarcoma
  • Poorly Differentiated Chordoma
  • ATRT
  • Malignant Rhabdoid Tumor of Kidney
  • Malignant Rhabdoid Tumor of Ovary
  • Malignant Rhabdoid Tumor
  • Myxoid Spindle Cell Sarcoma
  • Epithelioid Malignant Peripheral Nerve Sheath Tumor
  • Chondrosarcoma
  • Renal Cell Carcinoma
  • Myoepithelial Carcinoma
  • Synovial Sarcoma
  • Renal Medullary Carcinoma
  • Malignant Mesothelioma
  • Desmoplastic Small Round Cell Tumor (DSRCT)
  • Intramedullary Spinal Cord Schwannomatosis

Interventions

DRUG

Tazemetostat

Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene

Sponsors & Collaborators

  • Epizyme, Inc.

    lead INDUSTRY

Principal Investigators

  • Ipsen Medical Director · Ipsen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03874455 on ClinicalTrials.gov